Intravitreal Triamcinolone in Diabetic Retinopathy

Authors: Abraldes, Maximino J.; Fernandez, Maribel; Gomez-Ulla, Francisco

Source: Current Diabetes Reviews, Volume 5, Number 1, February 2009 , pp. 18-25(8)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $62.88 plus tax (Refund Policy)

Abstract:

Diabetic macular edema is an important cause of visual loss in the developed world and may frequently lead to irreversible changes in visual acuity. The Early Treatment Diabetic Retinopathy Study showed a significant benefit in using focal laser photocoagulation for the treatment of macular edema, more specifically defined as clinically significant macular edema. However, some cases of diabetic macular edema are refractory to laser therapy and do not have a good prognosis with such treatment. Triamcinolone acetonide is glucocoticosteroid with antiangiogenic and antiedematous properties. Recently, some promising results, respect to the increases of visual acuity and decreases in foveal thickness, have been shown in different studies for the treatment of refractory diabetic macular edema with intravitreal triamcinolone acetonide.

Keywords: Intravitreal triamcinolone; Diabetic macular edema; Diabetic retinopathy; Vitrectomy

Document Type: Research article

DOI: http://dx.doi.org/10.2174/157339909787314185

Publication date: 2009-02-01

More about this publication?

Current Diabetes Reviews publishes frontier reviews on all the latest advances on diabetes and its related areas e.g. pharmacology, pathogenesis, complications, epidemiology, clinical care, and therapy.

The journal's aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians who are involved in the field of diabetes.